多索茶碱联合双相气道正压治疗对老年慢性阻塞性肺疾病患者炎症因子、脂质运载蛋白1及缺氧诱导因子1α的影响  

Effects of Doxofylline Combined with Bidirectional Positive Airway Pressure on Inflammatory Factors, Lipocalin-1 and Hypoxia-Inducible Factor-1α in Elderly Patients with Chronic Obstructive Pulmonary Disease

作　　者：郑文旭 王彩静 张凤革 李怀远 ZHENG Wenxu;WANG Caijing;ZHANG Fengge;LI Huaiyuan(Dept.of General Practice Medicine,Pinggu Hospital of Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing 100200,China)

机构地区：[1]首都医科大学附属北京友谊医院平谷医院全科医疗科,北京100200

出　　处：《中国医院用药评价与分析》2022年第2期158-161,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：首都卫生发展科研专项资助项目(No.首发2019-4014-06)。

摘　　要：目的:探讨多索茶碱联合双相气道正压(BiPAP)治疗对老年慢性阻塞性肺疾病(COPD)患者炎症因子、脂质运载蛋白1(LCN1)及缺氧诱导因子1α(HIF-1α)的影响。方法:采用前瞻性研究,以2019—2020年该院诊治的80例老年COPD患者为研究对象,采用随机数字表法分为观察组和对照组,每组40例。两组患者均采用多索茶碱治疗,治疗4周;观察组患者在此基础上联合BiPAP治疗。比较两组患者的治疗效果,肺功能、炎症指标和血清LCN1、HIF-1α水平,以及不良反应发生情况的差异。结果:总有效率方面,对照组患者为75.00%(30/40),观察组患者为92.50%(37/40),组间比较,差异有统计学意义(U=2.152,P=0.032)。治疗后,两组患者的用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))和第1秒用力呼气容积百分比(FEV_(1)%)均较治疗前显著升高,且观察组患者的FVC(t=2.858,P=0.005)、FEV_(1)(t=2.957,P=0.004)和FEV_(1)%(t=8.065,P=0.000)显著高于对照组,差异均有统计学意义。治疗后,两组患者白细胞介素(IL)1β、肿瘤坏死因子α(TNF-α)和IL-6水平均较治疗前显著降低,且观察组患者IL-1β(t=13.457,P=0.000)、TNF-α(t=2.977,P=0.004)和IL-6(t=2.002,P=0.049)水平显著低于对照组,差异均有统计学意义。与治疗前相比,两组患者治疗后的LCN1水平显著升高,HIF-1α水平显著降低;且观察组患者的LCN1水平显著高于对照组(t=2.903,P=0.005),HIF-1α水平显著低于对照组(t=88.588,P=0.000),差异均有统计学意义。两组患者发热心悸、皮疹和腹泻恶心等不良反应发生率的差异无统计学意义(P>0.05)。结论:老年COPD患者采用多索茶碱联合BiPAP治疗,其LCN1水平显著升高,HIF-1α水平显著降低,炎症反应显著减轻,治疗效果显著。OBJECTIVE: To probe into the effects off doxofylline combined with bidirectional positive airway pressure(BiPAP) on inflammatory factors, lipocalin-1(LCN1) and hypoxia-inducible factor-1α(HIF-1α) in elderly patients with chronic obstructive pulmonary disease(COPD). METHODS: This was a prospective study, totally 80 elderly patients with COPD diagnosed and treated in this hospital from 2019 to 2020 were study subjects, which were extracted to be divided into observation group and control group via the random number table, with 40 cases in each group. Patients in both groups were treated with doxorubicin for 4 weeks, and the observation group was given BiPAP on this basis. Differences in therapeutic effects, pulmonary function, inflammatory indicators, serum LCN1 and HIF-1α levels, as well as the incidences of adverse drug reactions were compared between two groups. RESULTS: In terms of total effective rate, the control group was 75.00%(30/40), while in comparison, the observation group had a higher total effective rate of 92.50%(37/40), with statistically significant difference between two groups(U=2.152,P=0.032). After treatment, the forced vital capacity(FVC), forced expiratory volume in one second(FEV_(1)) and forced expiratory volume in one second percentage(FEV_(1)%) of both groups were significantly higher than before treatment, and the FVC(t=2.858,P=0.005), FEV_(1)(t=2.957,P=0.004) and FEV_(1)%(t=8.065,P=0.000) in the observation group were significantly higher than the control group, with statistically significant differences. After treatment, the interleukin(IL) 1β, tumor necrosis factor α(TNF-α) and IL-6 levels of both groups were significantly lower than before treatment, and the IL-1β(t=13.457,P=0.000), TNF-α(t=2.977,P=0.004) and IL-6(t=2.002,P=0.049) in the observation group were significantly lower than the control group, with statistically significant differences. Compared with before treatment, the LCN1 was significantly higher and HIF-1α was significantly lower in both groups;LCN1(t=2.903,

关 键 词：慢性阻塞性肺疾病 多索茶碱 双相气道正压 肺功能 脂质运载蛋白1 缺氧诱导因子1Α 

分 类 号：R974[医药卫生—药品]